Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We describe an MRI-pathologic cross-correlative approach using intrinsic susceptibility (IS) and susceptibility contrast (SC) MRI to noninvasively map the vascular phenotype in neuroblastoma Th-MYCN transgenic mice treated with the vascular endothelial growth factor receptor inhibitor cediranib.
|
30877107 |
2019 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present findings indicated that the interplay between the p53/caspase pathway and the linc01105/miR‑6769b‑5p/VEGFA axis may have important roles in the development of neuroblastoma.
|
31524279 |
2019 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Since BDNF is reported to stimulate VEGF expression and/or release in neuroblastoma cells, the present study tested the hypothesis that the actions of BDNF are mediated by VEGF.
|
30712809 |
2019 |
Neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The tumor growth model was coupled with known pharmacokinetics and pharmacodynamics of the VEGF blocker bevacizumab to study its effect on neuroblastoma growth dynamics.
|
29948886 |
2018 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genotyping of cPMSCs revealed fetal rather than maternal origin of the cells. cPMSCs were viable and mitotically expansive in a collagen hydrogel delivery vehicle, and they secreted the immunomodulatory and neurotrophic paracrine factors interleukin (IL)-6, IL-8, monocyte chemoattractant protein 1 (MCP-1), and vascular endothelial growth factor (VEGF). cPMSCs also stimulated the growth of complex neural networks when co-cultured with SH-SY5Y cells, a neuroblastoma cell line used to model neuron growth in vitro. cPMSCs are analogous to human PMSCs.
|
28715613 |
2018 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since melatonin has anti-angiogenic effects in tumor cell lines, the aim of the present study was to study melatonin modulation of the pro-angiogenic effects of VEGF in neuroblastoma cells (SH-SY5Y).
|
28259965 |
2017 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Therefore, we investigated the effect of coffee on VEGF expression in human neuroblastoma SH-SY5Y cells.
|
26788968 |
2017 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The rationale for studying the combination of bevacizumab, irinotecan, and temozolomide (BIT) in neuroblastoma (NB) is based on the following: (i) vascular endothelial growth factor (VEGF) expression is associated with an aggressive phenotype, (ii) anti-VEGF antibody bevacizumab enhances irinotecan-mediated suppression of NB xenografts, (iii) bevacizumab safety has been established in pediatric phase I studies, and (iv) irinotecan + temozolomide (IT) is a standard salvage chemotherapy.
|
28111925 |
2017 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, our findings suggest that VEGF is a favorable prognostic factor of NB and might affect NB tumor behavior through CRT-driven neuronal differentiation rather than angiogenesis that might shed light on a novel therapeutic strategy to improve the outcome of NB.
|
28894229 |
2017 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggest that PlGF and VEGF-A modulate MYCN-non-amplified NB tumors by different mechanisms and support a role for PlGF in NB biology.
|
27669225 |
2016 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This conclusion was based on in vitro transfection with pre-miR-93-5p and anti-miR-93-5p; these treatments inversely modulated both VEGF and IL-8 gene expression and protein release in the neuroblastoma SK-N-AS cell line.
|
26986724 |
2016 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Gain- and loss-of-function studies indicated that secretory ITLN1 facilitated the NDRG2 expression, resulting in down-regulation of vascular endothelial growth factor (VEGF) and matrix metalloproteinase 9 (MMP-9), in NB cell lines SH-SY5Y, SK-N-BE(2), and SK-N-SH.
|
25889839 |
2015 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We further examined the role of VEGF-A in the NB cell differentiation via VEGF receptor blockade.
|
25288151 |
2015 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study provides a new insight into the role of VEGFA in NBL metastases by pointing to the role of stroma-derived intracrine VEGFA in osteoblastogenesis.
|
25648303 |
2015 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gain- and loss-of-function studies demonstrated that miR-558 facilitated the transcript and protein levels of HPSE and its downstream gene, vascular endothelial growth factor, in NB cell lines.
|
25616966 |
2015 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Patients with high miR-337-3p expression had greater survival probability. miR-337-3p suppressed the promoter activity, nascent transcription, and expression of MMP-14, resulting in decreased levels of vascular endothelial growth factor, in cultured NB cell lines.
|
26084291 |
2015 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study was conducted to evaluate the expression of Ki-67, p53 and VEGF markers in tissues obtained from NB patients with different histologic types and stage.
|
24815448 |
2014 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We hypothesize that AURKA-mediated stabilization of N-Myc may affect VEGF expression and angiogenesis in neuroblastoma.
|
24439602 |
2014 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
More than 50% of neuroblastomas (NBs) present with haematogenous and/or lymphatic metastasis; however, little is known about the clinicopathological significance in NBs of the key lymphangiogenesis growth factors vascular endothelial growth factor (VEGF)-C and VEGF-D and the receptor VEGFR-3.
|
22804730 |
2012 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpression or knockdown of miR-9 responsively altered both the mRNA and protein levels of MMP-14 and its downstream gene, vascular endothelial growth factor, in cultured neuroblastoma cell lines SH-SY5Y and SK-N-SH.
|
22564723 |
2012 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MDM2 is a key inhibitor of p53 and a positive activator of hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) activity with an important role in neuroblastoma pathogenesis.
|
21484514 |
2011 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
IGFBP-2 enhances VEGF gene promoter activity and consequent promotion of angiogenesis by neuroblastoma cells.
|
21750048 |
2011 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
ALK knockdown was associated with marked reductions in vascular endothelial growth factor (VEGF) secretion, blood vessel density, and matrix metalloproteinases (MMPs) expression in vivo, suggesting a role for ALK in NB-induced neoangiogenesis and tumor invasion, confirming this gene as a fundamental oncogene in NB.
|
21829174 |
2011 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results indicate that VEGF(165) is up-regulated in NB and that there is a difference in the balance of isoform expression from anti-angiogenic VEGF(165)b to angiogenic VEGF(165).
|
20662003 |
2010 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of TrkA, TrkB, and VEGF mRNA was semi-quantitatively detected by reverse transcription-polymerase chain reaction (RT-PCR) in 51 cases of neuroblastomas.
|
20186105 |
2010 |